{
 "name": "原創生醫",
 "slug": "tw-6483",
 "aliases": [
  "原創生醫股份有限公司",
  "OBM",
  "6483"
 ],
 "ticker": "6483",
 "industry": "生技醫療業",
 "website": "http://www.i-obm.com",
 "summary": "原創生醫（6483）是興櫃的生技醫療類股公司，2011 年成立，2024 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "原創生醫股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "OBM",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2024-03-29",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2011-12-05",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "林柏裕",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "王朝暉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 668080000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://www.i-obm.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：OBM-B01（氰化物解毒霧化吸入複方）",
   "value": "降低氰化物暴露傷害｜TFDA同意進行第一期人體臨床試驗｜台灣",
   "unit": "",
   "as_of": "2026-08-03",
   "source": "https://www.i-obm.com/news/ndetail-3-31.html",
   "note": "官網重大訊息；同意試驗不等於藥品上市。主要成分另見2026-04-27 IRB公告為hydroxocobalamin與deferoxamine mesylate。尚未找到可確認的OBM-B01 NCT編號。"
  },
  {
   "claim": "管線：OBM-A01（RadProtect／amifostine）",
   "value": "輻射傷害預防｜一期已收12名受試者，準備重啟試驗（2023年度年報，2024-05-31刊印）｜美國（NCT歷史登錄地）",
   "unit": "",
   "as_of": "2024-05-31",
   "source": "https://www.i-obm.com/upload_files/shareholders-meeting-information/112_Annual_Report.pdf",
   "note": "PDF第71頁（印刷67）產品與開發過程；資料較舊，不當2026即時狀態。NCT02587442；地區另據 https://clinicaltrials.gov/api/v2/studies/NCT02587442 ，2015-10-27最後更新且目前UNKNOWN；不沿用舊RECRUITING，也不採2016預估日為催化劑。"
  },
  {
   "claim": "管線：OBM-CL（CCM-CL／Colistin後線抗生素劑型）",
   "value": "抗生素感染治療｜動物模型研究，後續授權尚待完整數據（2023年度年報，2024-05-31刊印）｜開發地區未揭露",
   "unit": "",
   "as_of": "2024-05-31",
   "source": "https://www.i-obm.com/upload_files/shareholders-meeting-information/112_Annual_Report.pdf",
   "note": "PDF第71頁（印刷67）產品與開發過程；資料較舊，不當2026即時狀態。同年報PDF第7頁（印刷3）及第127頁（印刷123）明列Colistin；官網另用CCM-CL名稱：https://www.i-obm.com/ 。"
  },
  {
   "claim": "管線：NE（緩釋型維他命C+E）",
   "value": "醫美市場緩釋型維他命C+E原料｜與S公司簽約開發，原創後續獨家供核心原料｜兩岸",
   "unit": "",
   "as_of": "2025-05-06",
   "source": "https://www.i-obm.com/news/ndetail-3-15.html",
   "note": "開發與原料供貨合約，未當成已取得藥證或授權金收入。公司未公開S公司名稱、精確簽約日及財務條款，不建立授權合作／金額facts。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6483.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}